Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?

In the Ticlid or Plavix Post-Stents (TOPPS) trial, 1016 patients undergoing successful coronary stent placement were randomized to receive aspirin and either ticlopidine or clopidogrel. In this trial, the dosages and regimens of ticlopidine and clopidogrel resembled more closely those used in most c...

Descripción completa

Detalles Bibliográficos
Autor principal: Berger, Peter B
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2000
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59605/
https://www.ncbi.nlm.nih.gov/pubmed/11714416
http://dx.doi.org/10.1186/cvm-1-2-083
_version_ 1782120083530711040
author Berger, Peter B
author_facet Berger, Peter B
author_sort Berger, Peter B
collection PubMed
description In the Ticlid or Plavix Post-Stents (TOPPS) trial, 1016 patients undergoing successful coronary stent placement were randomized to receive aspirin and either ticlopidine or clopidogrel. In this trial, the dosages and regimens of ticlopidine and clopidogrel resembled more closely those used in most catheterization laboratories than did the two previous randomized trials comparing ticlopidine and clopidogrel. The results of the TOPPS trial support the current practice of substituting ticlopidine for clopidogrel in stent patients.
format Text
id pubmed-59605
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-596052001-11-06 Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement? Berger, Peter B Curr Control Trials Cardiovasc Med Commentary In the Ticlid or Plavix Post-Stents (TOPPS) trial, 1016 patients undergoing successful coronary stent placement were randomized to receive aspirin and either ticlopidine or clopidogrel. In this trial, the dosages and regimens of ticlopidine and clopidogrel resembled more closely those used in most catheterization laboratories than did the two previous randomized trials comparing ticlopidine and clopidogrel. The results of the TOPPS trial support the current practice of substituting ticlopidine for clopidogrel in stent patients. BioMed Central 2000 2000-10-11 /pmc/articles/PMC59605/ /pubmed/11714416 http://dx.doi.org/10.1186/cvm-1-2-083 Text en Copyright © 2000 Current Controlled Trials Ltd
spellingShingle Commentary
Berger, Peter B
Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?
title Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?
title_full Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?
title_fullStr Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?
title_full_unstemmed Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?
title_short Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?
title_sort results of the ticlid or plavix post-stents (topps) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59605/
https://www.ncbi.nlm.nih.gov/pubmed/11714416
http://dx.doi.org/10.1186/cvm-1-2-083
work_keys_str_mv AT bergerpeterb resultsoftheticlidorplavixpoststentstoppstrialdotheyjustifytheswitchfromticlopidinetoclopidogrelaftercoronarystentplacement

Ejemplares similares